High Vista Strategies LLC Immunovant, Inc. Transaction History

High Vista Strategies LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$31.31 - $44.19 $450,206 - $635,408	14,379 Added 13.45%	121,287 $5.11 Million
Q3 2023 Nov 14, 2023	SELL	$18.55 - $39.96 $1.36 Million - $2.93 Million	-73,412 Reduced 40.71%	106,908 $4.1 Million
Q2 2023 Aug 14, 2023	BUY	$14.2 - $23.75 $234,598 - $392,373	16,521 Added 10.09%	180,320 $3.42 Million
Q1 2023 May 15, 2023	BUY	$15.27 - $19.72 $2.5 Million - $3.23 Million	163,799 New	163,799 $2.54 Million
Q1 2021 May 17, 2021	SELL	$13.08 - $49.6 $234,197 - $888,088	-17,905 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$22.61 - $38.9 $404,832 - $696,504	17,905 New	17,905 $630,000

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on High Vista Strategies LLC with notifications on news.